An open label multicenter study to evaluate the efficacy and tolerability of gemfibrozil in elderly hyperlipidemic patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 7, Issue 1, 1997, Pages 30-37

  Cortese, C ^a,h   Abate, G ^b   Averna, M ^c   Capurso, A ^d   Gnasso, A ^a   Motti, C ^e   Notarbartolo, A ^c   Oriente, G ^f   Pauciullo, P ^e   Piliego, T ^g   Postiglione, L ^f   Resta, F ^d   Troja, C ^b  

^a Univ di Catanzaro   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Ctro Ric sull'Aterosclerosi C   (Italy)

^g Divisione Medica   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Combined hyperlipidemia; Elderly; Gemfibrozil; Hypercholesterolemia; Hypertriglyceridemia

Indexed keywords

EID: 3943069140     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Castelli P, Wilson PN, Levy D, Anderson K (1989) Cardiovascular risk factor in the elderly. Am J Cardiol 63: 12H-19H.
2. Aronow WS (1990) Cardiac risk factors: still important in the elderly. Geriatrics 45: 71 -80.
3. Benfante R, Reed D (1990) Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 263: 393-396.
4. Rubin SM, Sidney S, Black DM, et al. (1990) High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 113: 916-920.
5. Welin L, Eriksson H, Larsson B, et al. (1991) Triglycerides, a major coronary risk factor in elderly men. A study of men born in 1913. Eur Heart J 12: 700-704.
6. Ettinger WH, Wahl PW, Kuller LH, et al. (1992) Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. Circulation 86: 858-869.
7. Tikkanen MJ (1988) Hypercholesterolemia in the elderly: Is drug treatment justified? Eur Heart J 9 (Suppl. D): 79-82.
8. Gordon DJ, Rifkind BM (1989) Treating high blood cholesterol in the older patient. Am J Cardiol 63: 48H-52H.
9. Ettinger WH (1989) Lipid levels and risk of atherosclerotic coronary heart disease in the older person. Med Clin North Am 73: 1525-1530.
10. Kafonek SD, Kwiterovich PQ (1990) Treatment of hypercholesterolemia in the elderly. Ann Intern Med 112: 723-724.
11. Margo A., Denke MD, Grundy SM (1990) Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern. Med 112: 780-792.
12. Cohen N, Gilbert (1992) Hyperlipidemia and the aged. Aust J Hosp Pharm 22: 238-243.
13. Kaukola S, Manninen V, Malkonen M, Ehnholm CH (1981) Gemfibrozil in the treatment of dyslipidemias in middle-aged male survivors of myocardial infarction. Acta Med Scand 209: 69-73.
14. Manninen V, Malkonen M, Eisalo S, et al. (1992) Gemfibrozil in the treatment of dyslipidemia. A 5-year follow-up study. Acta Med Scand (Suppl) 668: 82-87.
15. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. (1987) Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1381.
16. Lewis JE (1982) Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia. Angiology 33: 603-612.
17. Samuel P (1983) Effects of gemfibrozil on serum lipids. Am J Med 74: 23-27.
18. Galletti F, Gasparro MG, Sensi S (1989) A multicenter gemfibrozil study in type II diabetic patients with hyperlipidemia. In: Atherosclerosis and Cardiovascular Disease Descovich GC et al (eds) Editrice Compositori, Bologna, pp 937-942.
19. Averna MR, Barbagallo CM, Pata G, et al. (1991) Effects of two different administration regimens of gemfibrozil on plasma lipids, lipoproteins and apoproteins. Curr Ther Res 49: 47-53.
20. Notarbartolo A, Galletti F, Averna M, et al. (1993) Effects of gemfibrozil in hyperlipidemic patients with or without diabetes. Curr Ther Res 53: 381-393.
21. Bissonette R (1983) Use of gemfibrozil in patients with dyslipidemia: A double-blind comparison with placebo. Ann Intern Med 4.
22. Schwartzkopf W, Menzel B, Stern K, Kempf U (1985) Gemfibrozil bei Patienten mit primären Hyperlipoproteinämien. Vergleichende Untersuchung von 900 mg und 1200 mg-Dosierungen. Therapiewoche 35: 1388-1398.
23. Kovanen PT, Koskinen P, Manninen V (1986) A comparison of different formulations and dosage administrations of gemfibrozil. Am J Cardiol 57: 31G-34G.
24. Manninen V, Elo O, Frick MH, Haapa K, et al. (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260: 641-651.
25. Maenpaa H, Heinonen OP, Manninen V (1991) Medication compliance and serum lipid changes in the Helsinki Heart Study. Br J Clin Pharmacol 32: 409-415.
26. Assmann G, Lewis B, Mancini M, Stein Y (cochairmen) (1988) The recognition and management of hyperlipidemia in adults. A policy statement of the European Atherosclerosis Society. Eur Heart J 9: 571-600.
27. Kwiterovich PO, Coresh J, Bachorik PS (1993) Prevalence of hyperapoB-lipoproteinemia and other lipoprotein phenotypes in men (aged ≤50 years) and women (≤60 years) with coronary artery disease. Am J Cardiol 71: 631-639.
28. Brown G, Albers JJ, Fisher LD, et al. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298.
29. Roussouw JE, Lewis B, Rifkind BM (1990) The value of lowering cholesterol after myocardial infarction. N Enel J Med 323: 1112 1119.